Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
The report covers forecast and analysis for the oncology biosimilar market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based revenue (USD Million). The study includes drivers and restraints for the oncology biosimilar market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oncology biosimilar market on a global level.

In order to give the users of this report a comprehensive view on the oncology biosimilar market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, where test type, drug type, distribution channel and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new test type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis.

The study provides a decisive view on the oncology biosimilar market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

Based on test type, the oncology biosimilar market is segmented as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer and others. Based on the distribution channel, the oncology biosimilar market is segmented as retail pharmacies, hospital pharmacy, and online pharmacy. 

Increasing demand for affordable therapies due to the constant increase in cancer patients is one of the major driving factors of oncology biosimilar market. High medical expenses associated with cancer treatment; the lack of awareness and dearth of skilled personnel are factors that influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Canada, Mexico, Germany, Spain, Italy, France, UK, China, Japan, India, and Brazil. This segment includes demand for oncology biosimilar market based on individual segment and test types in all the regions and countries.

The report also includes detailed profiles of end players such as Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others. 

This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: by Test Type

	Breast Cancer
	Colorectal Cancer
	Blood Cancer
	Neutropenia Cancer
	Non-Small Cell Lung Cancer
	Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

	mAb
	Immunomodulators
	Hematopoietic Agents
	G-CSF 
	Others

Global Oncology Biosimilar Market: by Distribution Channel

	Retail Pharmacies
	Hospital Pharmacy
	Online Pharmacy

Global Oncology Biosimilar Market: by Region

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	Middle East and Africa